Results 111 to 120 of about 15,817 (194)

Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254] [PDF]

, 2008
Barclay, Stephen, Benhamou, Yves, Cameron, Sheila, Carman, William, Hayes, Peter C, Mills, Peter R, Mutimer, David, Pol, Stanislas   +7 more
core   +1 more source

Entecavir provides favorable virological control but minimal metabolic benefit in patients with Chronic Hepatitis B and MAFLD. [PDF]

Am J Transl Res
Wang B, Mo X, Wu X, Huang Y, Deng K, Liang Y, Lu Z, Wei H, Liang J, Huang Z.   +9 more
europepmc   +1 more source

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand [PDF]

, 2014

core   +1 more source

Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B. [PDF]

World J Hepatol
Ma SP, Wang L, Zhang YL, Wan X, Liu Q, Tang YL, Malhi LR, Ge SF.   +7 more
europepmc   +1 more source

Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. [PDF]

Mediterr J Hematol Infect Dis
Silva N, Duarte G, Medina S, Amarante GD, de Souza CA, Pagnano K.   +5 more
europepmc   +1 more source

A Rare Case of Myopathy Associated with Entecavir Initiation. [PDF]

J Pharm Technol
Overton C, Brock L, Betapudi B, Wells DA.   +3 more
europepmc   +1 more source

Monitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B. [PDF]

Clin Transl Gastroenterol
Hsu CC, Chen ZE, Chao FH, Chou CY, Chang YL, Chou YC, Hou MC, Wu JC, Su CW.   +8 more
europepmc   +1 more source

PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE: AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL [PDF]

, 2008
Connolly, M, Nielsen, SK, Currie, CJ, Poole, CD   +3 more
core   +1 more source

Genotype-specific Response to 144-week Entecavir Therapy for HBeAg-positive Chronic Hepatitis B with a Particular Focus on Histological Improvement: A Prospective Study. [PDF]

J Clin Transl Hepatol
Liu L, Xu Q, Lin S, Wei Z, Huang G.
europepmc   +1 more source

The effect of treatment cessation on HBsAg negativity in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)id analogues for more than three years. [PDF]

BMC Infect Dis
Senol Yilmaz A, Turker N.
europepmc   +1 more source